Picture of Zai Lab logo

ZLAB — Zai Lab News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Brief: Zai Lab Receives U.S. FDA Fast Track Designation For Zl-1310, A Dll3-Targeted Antibody-Drug Conjugate, For Treatment Of Extensive-Stage Small Cell Lung Cancer

May 19 (Reuters) - Zai Lab Ltd 9688.HK:

ZAI LAB RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR ZL-1310, A DLL3-TARGETED ANTIBODY-DRUG CONJUGATE, FOR TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

ZAI LAB LTD - TO INITIATE PIVOTAL STUDY FOR ZL-1310 IN 2025

Source text: ID:nBw5PTTCha

Further company coverage: 9688.HK

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Zai Lab

See all news